Heron Therapeutics (HRTX) Stock Forecast, Price Target & Predictions
HRTX Stock Forecast
Heron Therapeutics stock forecast is as follows: an average price target of $7.00 (represents a 274.33% upside from HRTX’s last price of $1.87) and a rating consensus of 'Buy', based on 2 wall street analysts offering a 1-year stock forecast.
HRTX Price Target
The average price target for Heron Therapeutics (HRTX) is $7.00 based on 1-year price targets from 2 Wall Street analysts in the past 3 months, with a price target range of $9.00 to $5.00. This represents a potential 274.33% upside from HRTX's last price of $1.87.
HRTX Analyst Ratings
According to 2 Wall Street analysts, Heron Therapeutics's rating consensus is 'Buy'. The analyst rating breakdown for HRTX stock is 0 'Strong Buy' (0.00%), 2 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Heron Therapeutics Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| May 16, 2024 | Carl Byrnes | Northland Securities | $9.00 | $3.22 | 179.50% | 381.28% |
| Mar 13, 2024 | Serge Belanger | Needham | $5.00 | $3.01 | 66.11% | 167.38% |
The latest Heron Therapeutics stock forecast, released on May 16, 2024 by Carl Byrnes from Northland Securities, set a price target of $9.00, which represents a 179.50% increase from the stock price at the time of the forecast ($3.22), and a 381.28% increase from HRTX last price ($1.87).
Heron Therapeutics Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | 2 |
| Avg Price Target | - | - | $7.00 |
| Last Closing Price | $1.87 | $1.87 | $1.87 |
| Upside/Downside | -100.00% | -100.00% | 274.33% |
In the current month, the average price target of Heron Therapeutics stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Heron Therapeutics's last price of $1.87. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Jun 12, 2024 | Rodman & Renshaw | - | Buy | Initialise |
| Mar 13, 2024 | Needham | Buy | Buy | Hold |
| Nov 15, 2023 | Needham | Buy | Buy | Hold |
Heron Therapeutics's last stock rating was published by Rodman & Renshaw on Jun 12, 2024. The company Initialise its HRTX rating from "null" to "Buy".
Heron Therapeutics Financial Forecast
Heron Therapeutics Revenue Forecast
| Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Dec 18 | Sep 18 | Jun 18 | Mar 18 | Dec 17 | Sep 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | $34.23M | $31.43M | - | $29.61M | $30.03M | $26.56M | - | $23.46M | $21.49M | $23.23M | $22.44M | $20.02M | $20.61M | $19.96M | $22.67M | $25.40M | $35.08M | $42.62M | $36.66M | $31.60M | $28.84M | $19.79M | $17.28M | $11.57M | $10.05M | $8.57M |
| Avg Forecast | $39.58M | $36.62M | $36.09M | $32.98M | $31.23M | $32.65M | $31.70M | $29.69M | $27.24M | $26.96M | $24.55M | $22.61M | $25.77M | $25.52M | $29.45M | $25.71M | $19.55M | $17.17M | $19.81M | $20.09M | $31.81M | $34.55M | $31.43M | $28.04M | $21.06M | $18.17M | $22.40M | $12.28M | $7.28M | $9.57M |
| High Forecast | $41.07M | $37.56M | $37.45M | $34.22M | $31.95M | $33.88M | $32.89M | $30.81M | $28.26M | $27.98M | $24.55M | $23.74M | $27.07M | $26.81M | $30.93M | $27.00M | $20.53M | $18.03M | $20.80M | $21.10M | $33.41M | $36.29M | $33.01M | $29.45M | $25.27M | $21.80M | $26.88M | $14.74M | $8.74M | $11.49M |
| Low Forecast | $38.59M | $36.14M | $35.18M | $32.15M | $30.49M | $31.83M | $30.90M | $28.94M | $26.55M | $26.28M | $24.55M | $21.55M | $24.57M | $24.33M | $28.08M | $24.51M | $18.64M | $16.37M | $18.89M | $19.16M | $30.33M | $32.94M | $29.96M | $26.73M | $16.85M | $14.54M | $17.92M | $9.83M | $5.83M | $7.66M |
| # Analysts | 1 | 3 | 1 | 1 | 2 | 1 | 1 | 1 | - | - | - | - | 2 | 2 | 2 | 7 | 10 | 10 | 10 | 10 | 6 | 6 | 6 | 6 | 15 | 14 | 11 | 16 | 13 | 12 |
| Surprise % | - | - | - | - | 1.10% | 0.96% | - | 1.00% | 1.10% | 0.99% | - | 1.04% | 0.83% | 0.91% | 0.76% | 0.78% | 1.05% | 1.16% | 1.14% | 1.26% | 1.10% | 1.23% | 1.17% | 1.13% | 1.37% | 1.09% | 0.77% | 0.94% | 1.38% | 0.90% |
Heron Therapeutics's average Quarter revenue forecast for Mar 24 based on 1 analysts is $32.98M, with a low forecast of $32.15M, and a high forecast of $34.22M. HRTX's average Quarter revenue forecast represents a -3.66% decrease compared to the company's last Quarter revenue of $34.23M (Dec 23).
Heron Therapeutics EBITDA Forecast
| Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Dec 18 | Sep 18 | Jun 18 | Mar 18 | Dec 17 | Sep 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 3 | 1 | 1 | 2 | 1 | 1 | 1 | - | - | - | - | 2 | 2 | 2 | 7 | 10 | 10 | 10 | 10 | 6 | 6 | 6 | 6 | 15 | 14 | 11 | 16 | 13 | 12 |
| EBITDA | - | - | - | - | $-9.51M | $-24.20M | - | $-32.34M | $-20.36M | $-41.18M | - | $-62.20M | $-56.26M | $-51.65M | $-60.28M | $-51.88M | $-61.57M | $-57.46M | $-54.45M | $-50.96M | $-57.36M | $-33.07M | $-49.73M | $-62.55M | $-49.14M | $-37.96M | $-38.34M | $-51.88M | $-60.49M | $-40.91M |
| Avg Forecast | $-38.38M | $-35.51M | $-34.99M | $-69.49M | $-30.28M | $-31.66M | $-30.73M | $-54.94M | $-26.41M | $-65.34M | $-23.80M | $-43.43M | $-60.14M | $-59.40M | $-57.22M | $-50.96M | $-58.73M | $-56.55M | $-57.00M | $-57.23M | $-30.85M | $-41.78M | $-50.51M | $-25.27M | $-30.98M | $-34.59M | $-47.10M | $-54.90M | $-37.52M | $-45.19M |
| High Forecast | $-37.41M | $-35.04M | $-34.11M | $-55.59M | $-29.56M | $-30.86M | $-29.96M | $-43.95M | $-25.75M | $-52.27M | $-23.80M | $-34.74M | $-48.11M | $-47.52M | $-45.77M | $-40.77M | $-46.98M | $-45.24M | $-45.60M | $-45.78M | $-29.41M | $-33.42M | $-40.41M | $-20.22M | $-24.78M | $-27.67M | $-37.68M | $-43.92M | $-30.02M | $-36.15M |
| Low Forecast | $-39.82M | $-36.42M | $-36.31M | $-83.39M | $-30.98M | $-32.85M | $-31.89M | $-65.92M | $-27.40M | $-78.41M | $-23.80M | $-52.11M | $-72.17M | $-71.28M | $-68.66M | $-61.16M | $-70.47M | $-67.86M | $-68.40M | $-68.68M | $-32.40M | $-50.13M | $-60.61M | $-30.33M | $-37.17M | $-41.51M | $-56.52M | $-65.88M | $-45.03M | $-54.23M |
| Surprise % | - | - | - | - | 0.31% | 0.76% | - | 0.59% | 0.77% | 0.63% | - | 1.43% | 0.94% | 0.87% | 1.05% | 1.02% | 1.05% | 1.02% | 0.96% | 0.89% | 1.86% | 0.79% | 0.98% | 2.47% | 1.59% | 1.10% | 0.81% | 0.95% | 1.61% | 0.91% |
undefined analysts predict HRTX's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Heron Therapeutics's previous annual EBITDA (undefined) of $NaN.
Heron Therapeutics Net Income Forecast
| Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Dec 18 | Sep 18 | Jun 18 | Mar 18 | Dec 17 | Sep 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 3 | 1 | 1 | 2 | 1 | 1 | 1 | - | - | - | - | 2 | 2 | 2 | 7 | 10 | 10 | 10 | 10 | 6 | 6 | 6 | 6 | 15 | 14 | 11 | 16 | 13 | 12 |
| Net Income | - | - | - | - | $-10.72M | $-25.01M | - | $-32.47M | $-27.21M | $-41.93M | - | $-64.85M | $-52.24M | $-52.41M | $-61.02M | $-52.61M | $-62.28M | $-58.23M | $-55.19M | $-51.58M | $-57.92M | $-33.59M | $-50.22M | $-63.01M | $-49.56M | $-38.35M | $-38.67M | $-52.27M | $-62.49M | $-41.87M |
| Avg Forecast | $-3.66M | $-6.89M | $-5.99M | $-70.29M | $-23.43M | $-44.55M | $-34.01M | $-55.56M | $-48.23M | $-66.30M | $-81.04M | $-43.92M | $-58.41M | $-60.27M | $-57.91M | $-51.69M | $-59.41M | $-57.30M | $-57.78M | $-57.93M | $-83.83M | $-42.44M | $-51.01M | $-25.46M | $-31.24M | $-34.94M | $-47.51M | $-55.30M | $-38.76M | $-46.25M |
| High Forecast | $-3.54M | $-6.07M | $-5.79M | $-56.23M | $-20.31M | $-43.09M | $-32.90M | $-44.45M | $-46.66M | $-53.04M | $-81.04M | $-35.14M | $-46.73M | $-48.22M | $-46.33M | $-41.35M | $-47.53M | $-45.84M | $-46.22M | $-46.34M | $-78.74M | $-33.95M | $-40.81M | $-20.37M | $-24.99M | $-27.95M | $-38.01M | $-44.24M | $-31.01M | $-37.00M |
| Low Forecast | $-3.83M | $-7.72M | $-6.28M | $-84.34M | $-26.55M | $-46.73M | $-35.68M | $-66.68M | $-50.59M | $-79.56M | $-81.04M | $-52.71M | $-70.10M | $-72.32M | $-69.50M | $-62.03M | $-71.29M | $-68.76M | $-69.33M | $-69.51M | $-89.30M | $-50.92M | $-61.21M | $-30.55M | $-37.49M | $-41.92M | $-57.01M | $-66.36M | $-46.51M | $-55.50M |
| Surprise % | - | - | - | - | 0.46% | 0.56% | - | 0.58% | 0.56% | 0.63% | - | 1.48% | 0.89% | 0.87% | 1.05% | 1.02% | 1.05% | 1.02% | 0.96% | 0.89% | 0.69% | 0.79% | 0.98% | 2.47% | 1.59% | 1.10% | 0.81% | 0.95% | 1.61% | 0.91% |
Heron Therapeutics's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. HRTX's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
Heron Therapeutics SG&A Forecast
| Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Dec 18 | Sep 18 | Jun 18 | Mar 18 | Dec 17 | Sep 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 3 | 1 | 1 | 2 | 1 | 1 | 1 | - | - | - | - | 2 | 2 | 2 | 7 | 10 | 10 | 10 | 10 | 6 | 6 | 6 | 6 | 15 | 14 | 11 | 16 | 13 | 12 |
| SG&A | - | - | - | - | $23.62M | $24.60M | - | $32.01M | $26.70M | $28.18M | - | $32.95M | $34.37M | $34.99M | $33.16M | $24.81M | $28.06M | $22.00M | $25.41M | $30.62M | $30.29M | $25.57M | $33.42M | $38.37M | $28.70M | $23.57M | $20.74M | $20.86M | $22.85M | $19.99M |
| Avg Forecast | $44.16M | $40.86M | $40.26M | $36.79M | $34.84M | $36.43M | $35.36M | $28.66M | $30.39M | $30.08M | $27.39M | $25.22M | $28.75M | $28.48M | $32.86M | $24.37M | $21.81M | $19.15M | $22.10M | $22.42M | $35.49M | $32.30M | $35.06M | $15.50M | $18.09M | $20.27M | $24.99M | $13.70M | $8.13M | $10.68M |
| High Forecast | $45.82M | $41.91M | $41.78M | $38.18M | $35.65M | $37.80M | $36.69M | $34.39M | $31.53M | $31.21M | $27.39M | $26.49M | $30.20M | $29.91M | $34.51M | $29.25M | $22.90M | $20.12M | $23.21M | $23.54M | $37.28M | $38.76M | $36.82M | $18.60M | $21.71M | $24.33M | $29.99M | $16.45M | $9.75M | $12.81M |
| Low Forecast | $43.05M | $40.32M | $39.25M | $35.87M | $34.02M | $35.51M | $34.47M | $22.93M | $29.62M | $29.32M | $27.39M | $24.04M | $27.41M | $27.15M | $31.32M | $19.50M | $20.79M | $18.26M | $21.07M | $21.37M | $33.84M | $25.84M | $33.43M | $12.40M | $14.47M | $16.22M | $19.99M | $10.96M | $6.50M | $8.54M |
| Surprise % | - | - | - | - | 0.68% | 0.68% | - | 1.12% | 0.88% | 0.94% | - | 1.31% | 1.20% | 1.23% | 1.01% | 1.02% | 1.29% | 1.15% | 1.15% | 1.37% | 0.85% | 0.79% | 0.95% | 2.47% | 1.59% | 1.16% | 0.83% | 1.52% | 2.81% | 1.87% |
Heron Therapeutics's average Quarter SG&A projection for Mar 24 is $36.79M, based on 1 Wall Street analysts, with a range of $35.87M to $38.18M. The forecast indicates a 55.79% rise compared to HRTX last annual SG&A of $23.62M (Dec 23).
Heron Therapeutics EPS Forecast
| Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Dec 18 | Sep 18 | Jun 18 | Mar 18 | Dec 17 | Sep 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 3 | 1 | 1 | 2 | 1 | 1 | 1 | - | - | - | - | 2 | 2 | 2 | 7 | 10 | 10 | 10 | 10 | 6 | 6 | 6 | 6 | 15 | 14 | 11 | 16 | 13 | 12 |
| EPS | - | - | - | - | $-0.07 | $-0.17 | - | $-0.27 | $-0.23 | $-0.38 | - | $-0.64 | $-0.51 | $-0.51 | $-0.62 | $-0.58 | $-0.68 | $-0.64 | $-0.61 | $-0.57 | $-0.65 | $-0.42 | $-0.63 | $-0.80 | $-0.63 | $-0.49 | $-0.54 | $-0.81 | $-0.97 | $-0.77 |
| Avg Forecast | $-0.02 | $-0.05 | $-0.04 | $-0.07 | $-0.15 | $-0.29 | $-0.22 | $-0.22 | $-0.32 | $-0.38 | $-0.54 | $-0.48 | $-0.58 | $-0.61 | $-0.56 | $-0.54 | $-0.65 | $-0.63 | $-0.62 | $-0.65 | $-0.56 | $-0.57 | $-0.61 | $-0.49 | $-0.29 | $-0.41 | $-0.86 | $-0.91 | $-0.49 | $-0.95 |
| High Forecast | $-0.02 | $-0.04 | $-0.04 | $-0.07 | $-0.13 | $-0.28 | $-0.22 | $-0.21 | $-0.31 | $-0.36 | $-0.54 | $-0.46 | $-0.54 | $-0.57 | $-0.52 | $-0.51 | $-0.61 | $-0.59 | $-0.58 | $-0.61 | $-0.52 | $-0.54 | $-0.57 | $-0.46 | $-0.23 | $-0.33 | $-0.69 | $-0.73 | $-0.39 | $-0.76 |
| Low Forecast | $-0.03 | $-0.05 | $-0.04 | $-0.08 | $-0.17 | $-0.31 | $-0.23 | $-0.23 | $-0.33 | $-0.39 | $-0.54 | $-0.52 | $-0.61 | $-0.65 | $-0.59 | $-0.58 | $-0.69 | $-0.67 | $-0.66 | $-0.70 | $-0.59 | $-0.61 | $-0.65 | $-0.52 | $-0.35 | $-0.49 | $-1.03 | $-1.09 | $-0.59 | $-1.14 |
| Surprise % | - | - | - | - | 0.46% | 0.58% | - | 1.25% | 0.73% | 1.01% | - | 1.32% | 0.88% | 0.84% | 1.11% | 1.07% | 1.05% | 1.02% | 0.98% | 0.87% | 1.17% | 0.74% | 1.03% | 1.64% | 2.17% | 1.20% | 0.63% | 0.89% | 1.97% | 0.81% |
According to undefined Wall Street analysts, Heron Therapeutics's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to HRTX previous annual EPS of $NaN (undefined).
Heron Therapeutics Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| XFOR | X4 Pharmaceuticals | $0.71 | $3.67 | 416.90% | Buy |
| HRTX | Heron Therapeutics | $1.87 | $7.00 | 274.33% | Buy |
| PDSB | PDS Bio | $3.00 | $9.00 | 200.00% | Buy |
| DAWN | Day One Biopharmaceuticals | $14.13 | $38.80 | 174.59% | Buy |
| ABOS | Acumen Pharmaceuticals | $2.60 | $7.00 | 169.23% | Buy |
| INZY | Inozyme Pharma | $6.00 | $14.67 | 144.50% | Buy |
| MREO | Mereo BioPharma Group | $4.28 | $6.75 | 57.71% | Buy |
| TERN | Terns Pharmaceuticals | $8.96 | $12.50 | 39.51% | Buy |
| HOOK | HOOKIPA Pharma | $4.99 | $3.00 | -39.88% | Buy |
HRTX Forecast FAQ
Is Heron Therapeutics a good buy?
Yes, according to 2 Wall Street analysts, Heron Therapeutics (HRTX) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 2 'Buy' recommendations, accounting for 100.00% of HRTX's total ratings.
What is HRTX's price target?
Heron Therapeutics (HRTX) average price target is $7 with a range of $5 to $9, implying a 274.33% from its last price of $1.87. The data is based on 2 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Heron Therapeutics stock go up soon?
According to Wall Street analysts' prediction for HRTX stock, the company can go up by 274.33% (from the last price of $1.87 to the average price target of $7), up by 381.28% based on the highest stock price target, and up by 167.38% based on the lowest stock price target.
Can Heron Therapeutics stock reach $3?
HRTX's average twelve months analyst stock price target of $7 supports the claim that Heron Therapeutics can reach $3 in the near future.
What are Heron Therapeutics's analysts' financial forecasts?
HRTX's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $145.27M (high $150.31M, low $142.06M), average EBITDA is $-178M (high $-162M, low $-196M), average net income is $-86.822M (high $-71.627M, low $-102M), average SG&A $162.07M (high $167.69M, low $158.49M), and average EPS is $-0.183 (high $-0.173, low $-0.195).
Did the HRTX's actual financial results beat the analysts' financial forecasts?
Based on Heron Therapeutics's last annual report (Dec 2023), the company's revenue was $192.15M, beating the average analysts forecast of $125.26M by 53.40%. Apple's EBITDA was $-111M, missing the average prediction of $-148M by -25.06%. The company's net income was $-111M, missing the average estimation of $-158M by -29.83%. Apple's SG&A was $116.66M, missing the average forecast of $135.29M by -13.77%. Lastly, the company's EPS was $-800, beating the average prediction of $-0.886 by 90227.06%. In terms of the last quarterly report (Dec 2023), Heron Therapeutics's revenue was $34.23M, beating the average analysts' forecast of $31.23M by 9.63%. The company's EBITDA was $-9.505M, missing the average prediction of $-30.276M by -68.61%. Heron Therapeutics's net income was $-10.724M, missing the average estimation of $-23.429M by -54.23%. The company's SG&A was $23.62M, missing the average forecast of $34.84M by -32.20%. Lastly, the company's EPS was $-0.0714, missing the average prediction of $-0.154 by -53.59%